Technical Analysis for ADMP - Adamis Pharmaceuticals Corporation
Grade | Last Price | % Change | Price Change |
---|---|---|---|
D | 1.145 | 2.23% | 0.03 |
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Down |
Historical ADMP trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
1,2,3 Pullback Bullish | Bullish Swing Setup | 2.68% | |
Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 2.68% | |
Narrow Range Bar | Range Contraction | 2.68% | |
NR7 | Range Contraction | 2.68% | |
Wide Bands | Range Expansion | 2.68% | |
Oversold Stochastic | Weakness | 2.68% | |
Doji - Bullish? | Reversal | 2.68% | |
Wide Bands | Range Expansion | 2.68% | |
Oversold Stochastic | Weakness | 2.68% | |
Stochastic Reached Oversold | Weakness | 3.60% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time | |
---|---|---|
60 Minute Opening Range Breakout | 41 minutes ago | |
Up 3% | 41 minutes ago | |
Up 2% | about 2 hours ago | |
Up 1% | about 2 hours ago | |
60 Minute Opening Range Breakdown | about 20 hours ago |
Get a Trading Assistant
- Earnings date: 03/29/2021
Adamis Pharmaceuticals Corporation Description
Adamis Pharmaceuticals Corporation, a biopharmaceutical company, engages in the development and commercialization of specialty pharmaceutical products in the therapeutic areas of oncology, immunology and infectious diseases, and allergy and respiratory. The company focuses on the development of small molecule compounds, which comprise APC-100, APC-200, and APC-300 for the treatment of human prostate cancer; telomerase vaccine technologies; and other vaccine technologies for providing protection against various viral infectious agents. Its products under development also comprise TeloB-VAX, a novel cell-based vaccine product for prostate cancer; and Savvy(C31G), a contraceptive gel. The company's allergy and respiratory product pipeline includes Epinephrine Injection USP 1, a pre-filled single dose syringe product for use in the emergency treatment of extreme acute allergic reactions or anaphylactic shock; APC-1000, a steroid hydrofluoroalkane (HFA) metered dose inhaler product for asthma and chronic obstructive pulmonary disease; APC-2000, a generic HFA bronchodilator; and APC-3000, an HFA pressurized metered dose nasal steroid for the treatment of seasonal and perennial allergic rhinitis. It has a strategic manufacturing, supply, and product development agreement with Beximco Pharmaceuticals Ltd. The company is based in San Diego, California.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Medicine Biopharmaceutical Immunology Infectious Diseases Pharmaceutical Products Prostate Cancer Respiratory Therapy Dosage Forms Asthma Allergy Pulmonary Disease Chronic Obstructive Pulmonary Disease Syringe Smoking Cessation C3 Inhaler Telomerase Bronchodilator Emergency Treatment Infectious Agents Metered Dose Inhaler Rhinitis
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 2.34 |
52 Week Low | 0.27 |
Average Volume | 22,046,186 |
200-Day Moving Average | 0.80 |
50-Day Moving Average | 1.03 |
20-Day Moving Average | 1.32 |
10-Day Moving Average | 1.30 |
Average True Range | 0.18 |
ADX | 34.05 |
+DI | 28.54 |
-DI | 24.38 |
Chandelier Exit (Long, 3 ATRs ) | 1.21 |
Chandelier Exit (Short, 3 ATRs ) | 1.56 |
Upper Bollinger Band | 1.70 |
Lower Bollinger Band | 0.94 |
Percent B (%b) | 0.23 |
BandWidth | 57.36 |
MACD Line | 0.02 |
MACD Signal Line | 0.09 |
MACD Histogram | -0.0652 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 1.21 | ||||
Resistance 3 (R3) | 1.22 | 1.19 | 1.20 | ||
Resistance 2 (R2) | 1.19 | 1.17 | 1.19 | 1.19 | |
Resistance 1 (R1) | 1.16 | 1.16 | 1.15 | 1.15 | 1.18 |
Pivot Point | 1.13 | 1.13 | 1.13 | 1.13 | 1.13 |
Support 1 (S1) | 1.10 | 1.11 | 1.09 | 1.09 | 1.06 |
Support 2 (S2) | 1.07 | 1.10 | 1.07 | 1.05 | |
Support 3 (S3) | 1.04 | 1.07 | 1.05 | ||
Support 4 (S4) | 1.03 |